The use of stem cells after spinal cord injury to repair damaged neurons and improve the function of paralyzed neural pathways continues to show promise as a potential future therapy. Now, new research from Drexel University College of Medicine and the University of Texas at Austin demonstrates that improved respiratory function can be obtained in rodents with spinal cord injuries after successfully transplanting a special class of neural cells called V2a interneurons. Findings from the new study were published recently in the Journal of Neurotrauma, in an article entitled “Transplantation of Neural Progenitors and V2a Interneurons after Spinal Cord Injury.”
“Our previous study was one of the first to show that V2a interneurons contribute to plasticity, or the ability of the spinal cord to achieve some level of self-repair,” explained senior study investigator Michael Lane, Ph.D., an assistant professor of neurobiology and anatomy at Drexel University College of Medicine. “This study capitalized on those findings by demonstrating that we can grow these cells from stem cells, that they survive in an injured spinal cord, and that they can actually improve recovery.”
Spinal cord injuries impact a wide range of motor systems, and recent evidence suggests the body is capable of spontaneous improvements through the growth of nerve fibers and the formation of new circuits. Dr. Lane’s laboratory is interested in studying—and strengthening—this natural phenomenon to treat a potentially fatal side effect of paralysis: poor respiratory health. Not only do patients with high-level injuries require mechanical assistance to breathe, but they are also prone to lung congestion and respiratory infections.
“By understanding the body’s own attempt at repair, we hope to amplify that process therapeutically with cell transplantation and rehabilitation,” noted lead study investigator Lyandysha Zholudeva, a doctoral candidate in Dr. Lane’s laboratory. “Now we’ve identified one of the cell types that contributes to the formation of new pathways that lead to plasticity.”
In the past several years, there has been a growing interest in using neural precursors—cells that can develop into the distinct types found in the brain—to augment plasticity and treat spinal cord injury. Neural cells work with all the other cell types of the body to produce the range of functions of the central nervous system, including circulation, respiration, and digestion.
Interneurons are particularly attractive candidates for the injured spinal cord because they relay signals between sensory and motor neurons. However, these cells are a diverse bunch, and it has remained unclear exactly what type of interneuron could survive and thrive in an injured spinal cord after transplantation. Lane and other researchers pinpointed V2a interneurons as a potential contender, since they are “excitatory” (have greater action potential) and typically grow in the right direction for repair.
“Stem cell transplantation is gaining interest both within science, and within clinical trials, but scientific evidence shows that some types of cells may actually limit recovery. So, you have to know what will happen to the cells you are putting in the body,” he said. “The transplantation field is moving into an era where there is more interest in tailoring cell therapies.”
In the current study, the research team differentiated embryonic stem cells into V2a interneurons and combined them with neural progenitor cells from a rodent spinal cord. Once combined, the V2a cells were transplanted into 30 animals with high cervical moderate-to-severe injuries.
One month following transplantation, the donor cells had survived and become mature neurons in all 30 animals. Recording activity of the diaphragm muscle, the researchers found that breathing significantly improved in the animals that had received V2a interneurons compared to the controls.
“Even this incremental difference reassures us that we have identified a cell type to really concentrate on and that we should continue to investigate its potential even further,” Ms. Zholudeva stated.
Moving forward, the researchers plan to continue to determine how to optimize the transplant dose best for growth and connectivity of V2a cells in the injured spinal cord. Lane said the potential contribution of V2a cells to functional recovery could be enhanced with rehabilitation, neural-interfacing, and activity-based therapies.
“For now, we’ve focused on one cell, and one time point after injury, so there is more work still to be done,” Dr. Lane concluded. “But it is a big advance—we have at least one cell that contributes to recovery, and one day that may lead to better treatments.”